| Species |
Human |
| Protein Construction |
HLA-A*01:01&B2M&MAGE-A3 (EVDPIGHLY) Tetramer [Gly25-Thr305(HLA-A*01:01), Ile21-Met119(B2M) and EVDPIGHLY peptide]
Accession # Q5SUL5(HLA-A*01:01)&P61769(B2M)&EVDPIGHLY |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
258 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa. |
| Synonyms |
Melanoma-associated antigen 3; MZ2-D; MZ2D; MZ2-D; CT1.3; MAGE-3 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
